Use of centrally developed pharmacoeconomic assessments for local formulary decisions

American Journal of Health-System Pharmacy

Volumn 63, Issue 17, 2006, Pages 1613-1618

  Tordoff, June M ^a   Murphy, John E ^b   Norris, Pauline T ^c   Reith, David M ^d  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF ARIZONA   (United States)

^c School of Pharmacy   (New Zealand)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Data collection; Decision making; Formularies; Hospital; Institutional; Methodology; Pharmacoeconomics; Pharmacy

Indexed keywords

CELECOXIB; DESFLURANE; DROTRECOGIN; GABAPENTIN; GATIFLOXACIN; INFLIXIMAB; LINEZOLID; MOXIFLOXACIN; ROFECOXIB; VENLAFAXINE; VORICONAZOLE; ZOLEDRONIC ACID;

ARTICLE; DECISION MAKING; DRUG FORMULARY; HOSPITAL PHARMACY; NEW ZEALAND; PHARMACIST; PRIORITY JOURNAL; PUBLIC HOSPITAL; QUESTIONNAIRE;

EID: 33748807794     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060027     Document Type: Article

References (34)

1. Statement on safe practice in an environment of resource limitation (draft). Wellington, New Zealand: Medical Council of New Zealand; 2005 Aug.
2. Mannebach MA, Ascione FJ, Gaither CA et al. Activities, functions, and structure of pharmacy and therapeutics committees in large teaching hospitals. Am J Health-Syst Pharm. 1999; 56:622-8.
3. Leach RH, Leach SJ. Drug and therapeutics committees in the United Kingdom in 1992. Pharm J. 1994; 253:61-3.
4. Tordoff JM, Norris PT, Kennedy JM et al. Processes for the assessment and introduction of new medicines in New Zealand hospitals. J Pharm Pract Res. 2004; 34:267-71.
5. Weekes LM, Brooks C. Drug and therapeutics committees in Australia: expected and actual performance. Br J Clin Pharmacol. 1996; 42:551-7.
6. Pedersen CA, Schneider PJ, Scheckelhoff J. ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing - 2004. Am J Health-Syst Pharm. 2005; 62:378-90.
7. Odedina FT, Sullivan J, Nash R et al. Use of pharmacoeconomic data in making hospital formulary decisions. Am J Health-Syst Pharm. 2002; 59:1441-4.
8. Pillans PI. Control of high cost medicines. N Z Med J. 1994; 107:5-6.
9. Plumridge RJ. Pharmacoeconomies: challenges in developing the fourth dimension of drug evaluation. J Pharm Pract Res. 2003; 33:287-9.
10. Drummond M, Cooke J, Walley T. Economic evaluation under managed competition: evidence from the UK. Soc Sci Med. 1997; 45:583-95.
11. Hoffmann C, Stoykova BA, Nixon J et al. Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities. Value Health. 2002; 5:71-8.
12. Spath HM, Charavel M, Morelle M et al. A qualitative approach to the use of economic data in the selection of medicines for hospital formularies: a French survey. Pharm World Sci. 2003; 25:269-75.
13. National Hospital Pharmaceutical Strategy, final version. Wellington, New Zealand: Pharmaceutical Management Agency; 2002.
14. Tordoff J, Norris P, Kennedy J et al. Quality use of medicines activities in New Zealand hospitals from 2000 to 2002. N Z Med J. 2005; 118:U1259.
15. Tordoff JM, Norris PT, Reith DM. Managing prices for hospital pharmaceuticals: a successful strategy for New Zealand? Value Health. 2005; 8:201-8.
16. Pharmaceutical Management Agency. New Zealand pharmaceutical schedule. Section H for hospital pharmaceuticals, November 2004. www.pharmac.govt.nz/pdf/ SectionH.pdf (accessed 2005 Jan 24).
17. Pharmaceutical Management Agency. Hospital pharmaceutical assessment database. www.pharmac.govt.nz/hpad (accessed 2005 Jul 7).
18. Pharmaceutical Management Agency. Hospital pharmaceutical assessment process summary. www.pharmac.govt. nz/pdf/summary.pdf (accessed 2005 Dec 14).
19. Pharmaceutical Management Agency. Hospital pharmaceutical assessment template for pharmaceutical suppliers. www.pharmac.govt.nz/pdf/ATPS.pdf (accessed 2005 Dec 14).
20. Pharmaceutical Management Agency. Guideline for clinical reviewers of economic analysis, www.pharmac.govt.nz/pdf/070305.pdf (accessed 2005 Dec 14).
21. Pharmaceutical Management Agency. Guidelines for DHBs on use of discussion documents. http://203.97.134.53/HPAD/Home/Downloads/Guidelines.pdf (accessed 2005 Dec 14).
22. Grabowski H, Mullins CD. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. Soc Sci Med. 1997; 45:535-44.
23. Commonwealth Department of Health and Aging. Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee including major submissions involving economic analyses, 2002. www.health.gov.au/internet/wcms/publishing.nsf/Content/health- pbs-general-pubs-guidelines-content.htm-copy2 (accessed 2005 Nov 11).
24. Aspinall SL, Good CB, Classman PA et al. The evolving use of cost-effectiveness analysis in formulary management within the Department of Veterans Affairs. Med Care. 2005; 43(7 suppl):20-6.
25. Canadian Coordinating Office for Health Technology Assessment About CCOHTA. www.ccohta.ca/entry_e.html (accessed 2005 Dec 14).
26. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. www.nice.org.uk (accessed 2005 Dec 14).
27. Academy of Managed Care Pharmacy. Format for formulary submissions, version 2.0. October 2002. www.amcp.org (accessed 2005 Dec 14).
28. Asscher AW, Parr GD, Whitmarsh VB. Towards the safer use of medicines. BMJ. 1995; 311:1003-6.
29. Sterne SC, Uchida KM, Iteen SA. Improving the presentation of drug information to pharmacy and therapeutics committees for formulary decisions. Am J Health-Syst Pharm. 1996; 53:1162-4.
30. University of Otago School of Pharmacy. PHCX 524 pharmacoeconomics and drug evaluation. Postgraduate diploma in clinical pharmacy sheet, http://pharmacy.otago.ac.nz/gfx/pdf_files/pharmpgdipclinpharm.pdf (accessed 2005 Dec 14).
31. Rucker TD, Schiff G. Drug formularies: myths-in-formation. Med Care. 1990; 28:928-42.
32. Institute for Safe Medication Practices. The truth about hospital formularies. ISMP Med Saf Alert. 2005; 10:2-3.
33. Jenkings KN, Barber N. What constitutes evidence in hospital new drug decision making? Soc Sci Med. 2004; 58:1757-66.
34. Hoyle J. Clinicians reject PHARMAC plan. Pharm Today. 2005; Jun:1,6.